Investor Overview

Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$1.75
Change (%) Stock is Up 0.01 (0.57%)
Volume100,042
Data as of 02/21/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
01/11/17Histogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine
– Data demonstrate significant improvement in cartilage quality over first 24 months after treatment, with stabilization and maturation thereafter out to 60 months –  – Improvements in cartilage quality were accompanied by consistent and statistically significant improvements in patient reported clinical outcomes as early as 3 to 6 months after implantation –  – Data underscore potential to provide a faster and more durable recovery for patients with cartilage defects in the knee – WALTHAM, M... 
Printer Friendly Version
11/10/16Histogenics Corporation Announces Third Quarter 2016 Financial and Operating Results
- NeoCart® Phase 3 Clinical Trial More than 75% Enrolled - - Enrollment On-Track to Complete by End of Second Quarter of 2017 - - Third Quarter Financing Expected to Fund Company to Phase 3 Data - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced ... 
Printer Friendly Version
10/27/16Histogenics Corporation to Announce Third Quarter 2016 Financial Results on November 10, 2016
WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended September 30, 2016 on November 10, 2016 before the market opens.  Histogenics’ management will host a conference call on Thursday, November 10, 2016 at 8:30 a.m. ET.  A question-and-answer session will follo... 
Printer Friendly Version
10/24/16Histogenics Corporation Provides NeoCart® Phase 3 Clinical Trial Enrollment Update
- 75% of Patients Enrolled in NeoCart Phase 3 Clinical Trial - WALTHAM, Mass., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that as of October 24, 2016 it had enrolled 183, or approximately three-quarters, of the 245 patients required to complete enrollment of its ongoing NeoCart Phase 3 clinical trial.  This trial is being conduc... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.